BioXcelLogo.png
BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
August 14, 2020 07:00 ET | BioXcel Therapeutics
SERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application (“NDA”) submission to U.S. Food and Drug Administration (“FDA”) planned for Q1 2021 ...
BioXcelLogo.png
BioXcel Therapeutics to Host Second Quarter 2020 Operating and Financial Results Conference Call and Webcast
August 07, 2020 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to...
BioXcelLogo.png
BioXcel Therapeutics to Participate in the Canaccord Genuity 40th Annual Growth Conference
August 06, 2020 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to...
BioXcelLogo.png
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
July 28, 2020 20:20 ET | BioXcel Therapeutics
NEW HAVEN, Conn., July 28, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the...
BioXcelLogo.png
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
July 27, 2020 16:21 ET | BioXcel Therapeutics
NEW HAVEN, Conn., July 27, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced that...
BioXcelLogo.png
BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
July 20, 2020 07:00 ET | BioXcel Therapeutics
Highly statistically significant improvements in PEC score observed vs. placebo (p<0.0001) at two hours in the SERENITY trials for both doses tested Statistically significant improvements in PEC...
BioXcelLogo.png
BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from Delirium and Agitation
July 09, 2020 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., July 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches...
BioXcelLogo.png
BioXcel Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Formulation for BXCL501 and Methods of Treating Agitation
July 07, 2020 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., July 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to...
BioXcelLogo.png
BioXcel Therapeutics Announces Appointment of Reina Benabou, M.D., Ph.D., as Chief Development Officer
June 23, 2020 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., June 23, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to...
BioXcelLogo.png
BioXcel Therapeutics Announces Appointment of William P. Kane as Chief Commercial Officer
June 16, 2020 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., June 16, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to...